<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001054.v1.p1" parentStudy="phs001054.v1.p1" createDate="2015-12-28" modDate="2016-01-04">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Co-Principal Investigators</td><td>Adam Resnick, PhD</td><td>The Children&#39;s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, PA, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Rameen Beroukhim, MD, PhD</td><td>Dana-Farber Cancer Institute, PA, Brigham and Women&#39;s Hospital, MA, Broad Institute of MIT and Harvard, MA, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Keith L. Ligon, MD, PhD</td><td>Dana-Farber Cancer Institute, PA, Boston Children&#39;s Hospital, MA, Brigham and Women&#39;s Hospital, MA, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Pratiti Bandopadhayay, MBBS, PhD</td><td>Dana-Farber Cancer Institute, PA, Boston Children&#39;s Hospital, MA, Broad Institute of MIT and Harvard, MA, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Lori Ramkissoon, PhD</td><td>Dana-Farber Cancer Institute, PA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genomic Characterization of Pediatric Low-Grade Gliomas</StudyNameEntrez>
	<StudyNameReportPage>Genomic Characterization of Pediatric Low-Grade Gliomas</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Pediatric low-grade gliomas (PLGGs) are the most common pediatric brain-tumor, with more than ten histologic subtypes recognized by the World Health Organization. We performed a genomic analysis of 230 PLGGs of which 73 had whole genome/RNA sequencing performed and show that MYB-QKI fusions define the seizure associated tumor, Angiocentric Glioma (AG). MYB-QKI fusions present in AGs contribute to tumorigenesis through three mechanisms: MYB activation by truncation, enhancer translocation driving aberrant MYB-QKI expression, and hemizygous loss of QKI, a tumor suppressor gene. Such interplay between three oncogenic mechanisms has diagnostic and therapeutic implications in AGs, and illustrates the functional complexity associated with rearrangements in cancer. </p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Excluded patients &#62; 21 years of age </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Bandopadhayay P, Ramkissoon, LA, Jain P, Bergthold G et al." title="MYB-QKI rearrangements in Angiocentric Glioma drive tumorigenicity through a tripartite mechanism." journal="Nature Genetics accepted Dec 2015"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Glioma"/>
		<Disease vocab_source="MESH" vocab_term="Astrocytoma"/>
	</Diseases>
	<Attributions>
		<Header title="Co-Principal Investigators">
			<AttName>Adam Resnick, PhD</AttName>
			<Institution>The Children&#39;s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, PA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Rameen Beroukhim, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, PA, Brigham and Women&#39;s Hospital, MA, Broad Institute of MIT and Harvard, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Keith L. Ligon, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, PA, Boston Children&#39;s Hospital, MA, Brigham and Women&#39;s Hospital, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Pratiti Bandopadhayay, MBBS, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, PA, Boston Children&#39;s Hospital, MA, Broad Institute of MIT and Harvard, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Lori Ramkissoon, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, PA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Payal Jain</AttName>
			<Institution>The Children&#39;s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, PA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Guillaume Bergthold, MD</AttName>
			<Institution>Dana-Farber Cancer Institute, PA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Azra Ligon, PhD</AttName>
			<Institution>Brigham and Women&#39;s Hospital, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Mark Kieran, MD</AttName>
			<Institution>Boston Children&#39;s Hospital, MA, Dana-Farber Cancer Institute, PA, USA</Institution>
		</Header>
		<Header title="Other Investigators">
			<AttName>Matthew D. Ducar</AttName>
			<Institution>Dana-Farber Cancer Institute, PA, USA</Institution>
		</Header>
		<Header title="Other Investigators">
			<AttName>Paul van Hummelen</AttName>
			<Institution>Dana-Farber Cancer Institute, PA, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
		<ConsentGroup groupNum="2" shortName="DS-NTT" longName="Disease-Specific (Nervous Tissue Tumors)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001054.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001054.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001054.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (Nervous Tissue Tumors)</ConsentName>
        <ConsentAbbrev>DS-NTT</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Nervous Tissue Tumors.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
